Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27621586 | 0.86 | LMNA (0.46) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL987906 | 0.86 | TSHR (0.65) | TSHRLMNACHRM2CHRM4CHRM1 | |
| Acetic Acid SCHEMBL11076307 | 0.80 | TSHR (0.58) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL9747539 | 0.78 | TSHR (0.59) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL3814630 | 0.78 | TSHR (0.55) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL3223981 | 0.77 | LMNA (0.40) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL955409 | 0.77 | TSHR (0.42) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL10403865 | 0.76 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1MAPT | |
| SCHEMBL18256719 | 0.76 | TSHR (0.52) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL3814641 | 0.76 | TSHR (0.52) | TSHRLMNACHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | disclosed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | disclosed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | disclosed |
| US-6503940-B2 | Aids therapy | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-01-07 | — | — | US | disclosed |
| US-6486200-B1 | Prodrugs for antimicrobial amidines | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-26 | — | — | US | disclosed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
| US-6242600-B1 | ANTIISCHEMIC AGENTS, ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0167451-B1 | A NEW PROCESS FOR PREPARING NOVEL N-(ACYLOXY-ALKOXY) CARBONYL DERIVATIVES USEFUL AS BIOREVERSIBLE PRODRUG MOIETIES FOR PRIMARY AND SECONDARY AMINE FUNCTIONS IN DRUGS | MERCK & CO. INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| US-4916230-A | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO., INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0167451-A2 | A new process for preparing novel N-(acyloxy-alkoxy) carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO. INC. (US) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | TSHR 729/4885LMNA 4029/4885CHRM2 2307/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | TSHR 729/4885LMNA 4029/4885CHRM2 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.